3 Best Value Stocks with Over 20% Upside in 2026, According to Analysts

Value stocks are shares of companies that appear undervalued relative to their fundamentals. This means their stock price looks low compared with what the business earns, owns, or is expected to generate in the future. They often come from mature, financially stable companies with steady cash flow, consistent profits, and strong balance sheets.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Value stocks tend to have lower valuation ratios, such as low price‑to‑earnings (P/E) or price‑to‑book (P/B) ratios, suggesting the market may be underpricing the company.

Now, let’s check the three value stocks that analysts have spotlighted. Each offers more than 20% upside potential from current levels.

Here Are This Week’s Stocks

BioCryst PharmaceuticalsBCRX -3.39% ▼ – This biotechnology company develops oral medicines for rare and serious diseases, including treatments for hereditary angioedema. It has a Strong Buy analyst consensus rating and an average price target of $21.63, implying a 140.01% upside potential from the current levels. The company’s P/E of 6.2x reflects a 74.6% discount to the Healthcare sector’s median of 24.43.

BioCryst stock jumped over 13% on Monday, following market speculation and a Betaville “uncooked” alert that a large U.S.-based biopharma, with over $15 billion market cap, is eyeing the company.

Post Holdings POST +0.49% ▲ – This packaged food company is focused on ready-to-eat cereals, snacks, and private-label nutrition products. Its average price target of $128.50 implies a 31.2% upside potential from the current levels. POST stock has a Strong Buy consensus rating. Trading at a P/E of 13.2x, the company is valued 37.7% below the Consumer Defensive sector’s median multiple of 21.2.

Last week, Post issued an additional $600 million of 6.250% senior notes due 2034, priced at 100.75% of principal. The new notes join an existing $600 million series.

Amdocs DOX +0.38% ▲  – This software and services provider helps telecom and media companies manage customer experiences, billing, and digital operations. It has a Strong Buy analyst consensus rating and an average price target of $92.33, implying a 32.45% upside potential from the current levels. With a P/E ratio of 13.88x, the stock is priced at a 55.1% discount to the Technology sector’s median of 30.89.

Recently, Amdocs launched an AI‑powered app‑modernization effort with NVIDIA NVDA -0.26% ▼ , combining its agentic services with NVIDIA’s GPUs, NeMo, NIM microservices, and Agent Toolkit.

Disclaimer & DisclosureReport an Issue